SCHEMBL6309368

SCHEMBL6309368

NC(=O)c1ccn(CCCNC2CCC2)n1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 4/20 0.44
▸ POLB P06746 2/20 0.44
▸ TDP1 Q9NUW8 1/20 0.44
▸ CXCR4 P61073 3/20 0.40
▸ ALDH1A1 P00352 5/20 0.36
▸ KDM4E B2RXH2 3/20 0.36
▸ MEN1 O00255 2/20 0.36
▸ PAICS P22234 1/20 0.35
▸ FAAH O00519 1/20 0.35
▸ HDAC3 O15379 1/20 0.35
▸ CDK2 P24941 1/20 0.35
▸ HDAC4 P56524 1/20 0.35
▸ HDAC1 Q13547 1/20 0.35
▸ HDAC7 Q8WUI4 1/20 0.35
▸ HDAC2 Q92769 1/20 0.35
▸ HDAC10 Q969S8 1/20 0.35
▸ HDAC11 Q96DB2 1/20 0.35
▸ HDAC8 Q9BY41 1/20 0.35
▸ HDAC6 Q9UBN7 1/20 0.35
▸ HDAC9 Q9UKV0 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6305461 0.97 KMT2A (0.46) KMT2APOLBTDP1CXCR4ALDH1A1
SCHEMBL6302534 0.81 TDP1 (0.37) KMT2APOLBTDP1KDM4E
SCHEMBL6309369 0.80 CXCR4 (0.38) KMT2APOLBCXCR4ALDH1A1KDM4E
SCHEMBL6305041 0.77 KDM4C (0.36) KMT2APOLBTDP1ALDH1A1KDM4E
SCHEMBL6305463 0.77 CXCR4 (0.41) KMT2APOLBCXCR4ALDH1A1KDM4E
SCHEMBL6302961 0.76 ALDH1A1 (0.38) KMT2APOLBTDP1ALDH1A1KDM4E
SCHEMBL6309307 0.75 CYP1A2 (0.36) KMT2APOLBTDP1ALDH1A1KDM4E
SCHEMBL6302334 0.75 ALDH1A1 (0.37) KMT2APOLBTDP1ALDH1A1KDM4E
SCHEMBL6309532 0.74 ALDH1A1 (0.37) KMT2APOLBTDP1ALDH1A1KDM4E
SCHEMBL6308791 0.74 PARP1 (0.41) POLBALDH1A1KDM4ESMN1; SMN2PARP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor YOHANNES DANIEL (US) 2004-06-10 — — US claimed
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor PFIZER INC 2003-06-05 — — US claimed
US-6949562-B2 Heterocyclic compounds as ligands of the GABAA receptor NEUROGEN CORPORATION (US) 2005-09-27 — — US disclosed
US-6653471-B2 Tricyclic heteroaromatic compounds containing pyrrole ring; central nervous system disorder treatment; side effect reduction NEUROGEN CORPORATION 2003-11-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030105081-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885POLB 3619/4885TDP1 2846/4885
US-20040110778-A1 Heterocyclic compounds as ligands of the GABAA receptor GABRB1, GABRP, GABRA1 KMT2A 2120/4885POLB 3619/4885TDP1 2846/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback